Latest Governance News

Page 213 of 522
Invion Limited has affirmed its compliance with ASX disclosure rules following the US FDA’s granting of Orphan Drug Designation for its anal cancer treatment candidate INV043. The company detailed the timing and verification process behind its announcement.
Ada Torres
Ada Torres
28 Aug 2025
Tetratherix Limited reports its first financial results as a listed company, revealing a $9.4 million statutory loss driven by R&D and listing costs, alongside a robust $29.3 million cash position post-IPO. The company highlights key operational milestones and outlines strategic plans to accelerate commercialisation across its innovative biomaterial platform.
Ada Torres
Ada Torres
28 Aug 2025
Perpetual Limited reported a steady FY25 with underlying profit after tax of $204.1 million, revenue growth across all segments, and a net loss narrowed to $58.2 million. The firm’s refreshed strategy focuses on simplification, operational excellence, and measured growth investments amid evolving regulatory landscapes.
Claire Turing
Claire Turing
28 Aug 2025
Pengana Capital Group Limited has reported a strong turnaround for FY2025, posting a $2.61 million profit after tax and a 42% increase in revenue to $60.5 million, driven by growth in private credit and performance fees.
Claire Turing
Claire Turing
28 Aug 2025
Lynas Rare Earths has launched a fully underwritten A$750 million equity raising to fund its ambitious Towards 2030 growth strategy, aiming to expand rare earths production and downstream capabilities outside China.
Maxwell Dee
Maxwell Dee
28 Aug 2025
Lynas Rare Earths reported FY25 results featuring record NdPr output and the first commercial heavy rare earths production outside China, alongside a $750 million equity raise to fund its ambitious Towards 2030 growth strategy.
Maxwell Dee
Maxwell Dee
28 Aug 2025
Lynas Rare Earths reports FY25 revenue growth amid profit decline, completes major capital projects, and launches a $750 million equity raise to fund its expansive Towards 2030 strategy.
Maxwell Dee
Maxwell Dee
28 Aug 2025
Lynas Rare Earths reported a 20% revenue increase in FY25 driven by higher NdPr sales, yet net profit fell sharply amid ramp-up costs and market challenges. The company completed key growth projects and unveiled its Towards 2030 strategy focused on downstream expansion.
Maxwell Dee
Maxwell Dee
28 Aug 2025
Emyria Limited reports a reduced net loss of $3.14 million for FY2025, driven by strategic expansion in psychedelic-assisted mental health treatments and key partnerships including insurer Medibank. The company advances clinical services while continuing R&D on proprietary medicines.
Ada Torres
Ada Torres
28 Aug 2025
BetMakers Technology Group reported a 10.6% revenue decline to $85.1 million for FY25 but achieved positive adjusted EBITDA and operating cash flow for the first time, signaling a strategic turnaround.
Sophie Babbage
Sophie Babbage
28 Aug 2025
Comms Group Limited reported a 2.1% revenue increase to $56.6 million for FY25, driven by organic growth and the strategic acquisition of TasmaNet. Despite this, underlying EBITDA declined 13.6%, reflecting investments and one-off revenue adjustments.
Sophie Babbage
Sophie Babbage
28 Aug 2025
Micro-X reported FY25 revenue of $13.1 million, underpinned by significant US government contracts and pioneering 3D head CT imaging technology, setting the stage for clinical trials and commercial expansion.
Victor Sage
Victor Sage
28 Aug 2025